Scholarlink

<p>Ticagrelor is a P2Y12 inhibitor used to reduce thrombotic events in acute coronary syndrome (ACS). Optimal dosing is crucial for preventing bleeding and thrombosis; therefore, we developed the population pharmacokinetics (PK) of ticagrelor by incorporating results from previous population PK studies. Studies were identified through a PubMed search, and an integrated PK model was developed using pooled synthetic datasets. Two published PK models generated virtual cohorts of 1,000 individuals each with covariates of age, sex, weight, and smoking status. A one-compartment model with a parent–metabolite relationship was used to describe ticagrelor and its active metabolite. The final model estimated ticagrelor Ka at 0.613&#xa0;h⁻¹, oral clearance (CL/F) at 13.3&#xa0;L/h and apparent volume of distribution (Vd/F) of 228&#xa0;L; the metabolite showed oral clearance (CLM/F) of 9.75&#xa0;L/h and apparent volume of distribution (VM/F) of 4.59&#xa0;L. Simulations showed that elderly patients and smokers receiving 90&#xa0;mg twice-daily frequently exceeded the upper safety threshold (Cmin, ss &gt; 360 ng/mL), whereas a 60&#xa0;mg twice-daily regimen maintained exposure within the target therapeutic range (180–360 ng/mL). These hypothesis-generating findings warrant prospective validation in diverse ACS populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A pooled population pharmacokinetic analysis of ticagrelor in acute coronary syndrome using simulated data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月13日

查看全文
  • Ji Woo Lim,
  • Hyeeun Kim,
  • Heungjo Kim,
  • Hongjae Lee,
  • Kyongkuk Ryu,
  • Min Jung Chang

摘要

Ticagrelor is a P2Y12 inhibitor used to reduce thrombotic events in acute coronary syndrome (ACS). Optimal dosing is crucial for preventing bleeding and thrombosis; therefore, we developed the population pharmacokinetics (PK) of ticagrelor by incorporating results from previous population PK studies. Studies were identified through a PubMed search, and an integrated PK model was developed using pooled synthetic datasets. Two published PK models generated virtual cohorts of 1,000 individuals each with covariates of age, sex, weight, and smoking status. A one-compartment model with a parent–metabolite relationship was used to describe ticagrelor and its active metabolite. The final model estimated ticagrelor Ka at 0.613 h⁻¹, oral clearance (CL/F) at 13.3 L/h and apparent volume of distribution (Vd/F) of 228 L; the metabolite showed oral clearance (CLM/F) of 9.75 L/h and apparent volume of distribution (VM/F) of 4.59 L. Simulations showed that elderly patients and smokers receiving 90 mg twice-daily frequently exceeded the upper safety threshold (Cmin, ss > 360 ng/mL), whereas a 60 mg twice-daily regimen maintained exposure within the target therapeutic range (180–360 ng/mL). These hypothesis-generating findings warrant prospective validation in diverse ACS populations.